Belgium-based PanTera and US-based TerraPower Isotopes have signed a strategic cooperation agreement to increase the global production of actinium-225 (Ac-225), a promising radioisotope for the treatment of a wide array of cancers, which is presently undergoing clinical trials.
PanTera said in a statement that the two companies are planning to use TerraPower’s natural decay method based on thorium-229 and PanTera’s “gamma route” based on radium-226 to produce Ac-225 in the “near-term”.